5:09 PM ET
8-K
Business Update
CervoMed Business Update
CervoMed announced pharmacokinetic and regulatory updates for its lead drug candidate, neflamapimod, including a new 50 mg oral tablet formulation and the FDA's removal of a previous drug exposure limit. These developments allow the company to advance a 100 mg twice-daily dosing regimen in future clinical trials, which is expected to achieve higher drug concentrations and improve patient convenience compared to prior three-times-daily dosing.